According to drugmaker Jazz Pharmaceuticals, the antibody binds to two extracellular sites on HER2, the first and only such ...

Learn more about a new treatment for biliary tract cancers with high levels of HER2. The drug zanidatamab has been approved ...

Biliary tract disease describes any disease that affects the biliary tract the gall bladder, bile ducts and accompanying structures. Examples include primary sclerosing cholangitis, secondary ...

The bispecific antibody zanidatamab is now the first HER2-targeted therapy approved for patients with locally advanced or metastatic HER2-positive biliary tract cancer.

Individuals with primary biliary cholangitis and diabetes may experience worse outcomes, such as progression to end-stage ...

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug.

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.

Once clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the ...

Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...

The agency has approved Ziihera for adults with previously treated, unresectable or metastatic HER2-positive biliary tract ...

whose best example is the association between celiac disease (CD) and primary biliary cirrhosis (PBC). CD and PBC are two autoimmune disorders whose association has been widely established (mean ...

Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.